vs

Side-by-side financial comparison of CHIMERA INVESTMENT CORP (CIM) and Organogenesis Holdings Inc. (ORGO). Click either name above to swap in a different company.

CHIMERA INVESTMENT CORP is the larger business by last-quarter revenue ($66.2M vs $37.2M, roughly 1.8× Organogenesis Holdings Inc.). On growth, CHIMERA INVESTMENT CORP posted the faster year-over-year revenue change (0.5% vs -57.1%). Over the past eight quarters, CHIMERA INVESTMENT CORP's revenue compounded faster (0.8% CAGR vs -46.5%).

Chimera Investment Corp is a US-based real estate investment trust (REIT) primarily investing in residential mortgage-backed securities, residential and commercial mortgage loans, and other real estate-related financial assets. It delivers sustainable risk-adjusted returns for shareholders via regular dividend distributions from its investment portfolio.

Organogenesis Holdings Inc. is a leading regenerative medicine firm specializing in developing and manufacturing advanced therapeutic products for wound care, surgical repair, sports medicine, and dermatology. It serves healthcare providers and patients primarily in the U.S. and select international markets, offering clinically validated solutions for unmet medical needs.

CIM vs ORGO — Head-to-Head

Bigger by revenue
CIM
CIM
1.8× larger
CIM
$66.2M
$37.2M
ORGO
Growing faster (revenue YoY)
CIM
CIM
+57.6% gap
CIM
0.5%
-57.1%
ORGO
Faster 2-yr revenue CAGR
CIM
CIM
Annualised
CIM
0.8%
-46.5%
ORGO

Income Statement — Q4 FY2025 vs Q1 FY2026

Metric
CIM
CIM
ORGO
ORGO
Revenue
$66.2M
$37.2M
Net Profit
$28.3M
Gross Margin
30.8%
Operating Margin
42.6%
-185.1%
Net Margin
42.8%
Revenue YoY
0.5%
-57.1%
Net Profit YoY
119.3%
EPS (diluted)
$0.05

Green = leading value per metric. Periods may differ when fiscal calendars don't align.

8-Quarter Revenue & Profit Trend

Side-by-side quarterly history. Quarters aligned by calendar period so offset fiscal years line up.

Revenue
CIM
CIM
ORGO
ORGO
Q1 26
$37.2M
Q4 25
$66.2M
$225.6M
Q3 25
$65.0M
$150.9M
Q2 25
$66.0M
$101.0M
Q1 25
$69.2M
$86.7M
Q4 24
$65.8M
$126.7M
Q3 24
$66.5M
$115.2M
Q2 24
$67.3M
$130.2M
Net Profit
CIM
CIM
ORGO
ORGO
Q1 26
Q4 25
$28.3M
$43.7M
Q3 25
$-580.0K
$21.6M
Q2 25
$35.5M
$-9.4M
Q1 25
$167.3M
$-18.8M
Q4 24
$-146.5M
$7.7M
Q3 24
$136.5M
$12.3M
Q2 24
$56.7M
$-17.0M
Gross Margin
CIM
CIM
ORGO
ORGO
Q1 26
30.8%
Q4 25
Q3 25
Q2 25
Q1 25
72.6%
Q4 24
75.5%
Q3 24
76.7%
Q2 24
77.6%
Operating Margin
CIM
CIM
ORGO
ORGO
Q1 26
-185.1%
Q4 25
42.6%
28.1%
Q3 25
-0.5%
13.7%
Q2 25
54.3%
-12.5%
Q1 25
-30.9%
Q4 24
-222.6%
8.1%
Q3 24
5.4%
Q2 24
84.2%
-10.7%
Net Margin
CIM
CIM
ORGO
ORGO
Q1 26
Q4 25
42.8%
19.4%
Q3 25
-0.9%
14.3%
Q2 25
53.7%
-9.3%
Q1 25
241.7%
-21.7%
Q4 24
-222.6%
6.1%
Q3 24
205.4%
10.7%
Q2 24
84.2%
-13.1%
EPS (diluted)
CIM
CIM
ORGO
ORGO
Q1 26
Q4 25
$0.05
$0.31
Q3 25
$-0.27
$0.11
Q2 25
$0.17
$-0.10
Q1 25
$1.77
$-0.17
Q4 24
$-2.06
$0.05
Q3 24
$1.39
$0.09
Q2 24
$0.41
$-0.13

Balance Sheet & Financial Strength

Snapshot of each company's liquidity, leverage and book value from the latest quarter.

Metric
CIM
CIM
ORGO
ORGO
Cash + ST InvestmentsLiquidity on hand
$278.6M
$91.4M
Total DebtLower is stronger
$251.5M
Stockholders' EquityBook value
$2.6B
Total Assets
$15.8B
$520.0M
Debt / EquityLower = less leverage
0.10×

8-quarter trend — quarters aligned by calendar period.

Cash + ST Investments
CIM
CIM
ORGO
ORGO
Q1 26
$91.4M
Q4 25
$278.6M
$93.7M
Q3 25
$491.5M
$63.7M
Q2 25
$250.2M
$73.1M
Q1 25
$253.3M
$110.0M
Q4 24
$84.0M
$135.6M
Q3 24
$97.3M
$94.3M
Q2 24
$162.3M
$89.9M
Total Debt
CIM
CIM
ORGO
ORGO
Q1 26
Q4 25
$251.5M
Q3 25
$251.0M
Q2 25
$135.2M
Q1 25
$134.9M
Q4 24
$134.6M
Q3 24
$134.4M
$62.3M
Q2 24
$62.4M
$63.8M
Stockholders' Equity
CIM
CIM
ORGO
ORGO
Q1 26
Q4 25
$2.6B
$300.1M
Q3 25
$2.6B
$255.1M
Q2 25
$2.6B
$233.2M
Q1 25
$2.6B
$242.9M
Q4 24
$2.5B
$262.9M
Q3 24
$2.7B
$278.5M
Q2 24
$2.6B
$263.5M
Total Assets
CIM
CIM
ORGO
ORGO
Q1 26
$520.0M
Q4 25
$15.8B
$598.7M
Q3 25
$15.1B
$509.8M
Q2 25
$14.9B
$461.1M
Q1 25
$13.2B
$467.4M
Q4 24
$13.1B
$497.9M
Q3 24
$13.7B
$446.3M
Q2 24
$13.1B
$443.2M
Debt / Equity
CIM
CIM
ORGO
ORGO
Q1 26
Q4 25
0.10×
Q3 25
0.10×
Q2 25
0.05×
Q1 25
0.05×
Q4 24
0.05×
Q3 24
0.05×
0.22×
Q2 24
0.02×
0.24×

Cash Flow & Capital Efficiency

How much cash each business actually produces after reinvestment. Cash flow is harder to manipulate than net income.

Metric
CIM
CIM
ORGO
ORGO
Operating Cash FlowLast quarter
$-248.9M
Free Cash FlowOCF − Capex
FCF MarginFCF / Revenue
Capex IntensityCapex / Revenue
Cash ConversionOCF / Net Profit
-8.78×
TTM Free Cash FlowTrailing 4 quarters

8-quarter trend — quarters aligned by calendar period.

Operating Cash Flow
CIM
CIM
ORGO
ORGO
Q1 26
Q4 25
$-248.9M
$39.4M
Q3 25
$-137.5M
$3.1M
Q2 25
$-7.4M
$-32.9M
Q1 25
$48.8M
$-19.9M
Q4 24
$205.7M
$10.9M
Q3 24
$41.4M
$8.7M
Q2 24
$69.0M
$4.7M
Free Cash Flow
CIM
CIM
ORGO
ORGO
Q1 26
Q4 25
$34.8M
Q3 25
$844.0K
Q2 25
$-36.5M
Q1 25
$-23.6M
Q4 24
$7.6M
Q3 24
$6.1M
Q2 24
$2.9M
FCF Margin
CIM
CIM
ORGO
ORGO
Q1 26
Q4 25
15.4%
Q3 25
0.6%
Q2 25
-36.1%
Q1 25
-27.2%
Q4 24
6.0%
Q3 24
5.3%
Q2 24
2.2%
Capex Intensity
CIM
CIM
ORGO
ORGO
Q1 26
Q4 25
2.1%
Q3 25
1.5%
Q2 25
3.6%
Q1 25
4.2%
Q4 24
2.7%
Q3 24
2.2%
Q2 24
1.4%
Cash Conversion
CIM
CIM
ORGO
ORGO
Q1 26
Q4 25
-8.78×
0.90×
Q3 25
0.14×
Q2 25
-0.21×
Q1 25
0.29×
Q4 24
1.43×
Q3 24
0.30×
0.71×
Q2 24
1.22×

Financial Flow Comparison

Revenue → gross profit → operating profit → net profit for each company.

Related Comparisons